Table 3.

Cumulative Annualized Incidence Rates for Clinical Outcomes in the Women's Health Initiative Calcium and Vitamin D Supplementation Trial According to Baseline Total Vitamin D Intake, IU/Day

	Overall combined phases
	CaD		Placebo
	N	%	N	%	HRa	(95% CI)a	p-valuea
Hip fracture							0.97
<200	138	0.18	140	0.19	0.93	(0.74, 1.18)
200–<400	68	0.18	75	0.20	0.95	(0.68, 1.33)
400–<600	80	0.17	112	0.24	0.74	(0.55, 0.98)
≥600	87	0.23	77	0.21	1.07	(0.79, 1.46)
Vertebral fractureb							0.70
<200	143	0.19	156	0.21	0.88	(0.70, 1.11)
200–<400	79	0.21	93	0.25	0.85	(0.63, 1.15)
400–<600	100	0.22	127	0.27	0.78	(0.60, 1.01)
≥600	116	0.31	127	0.35	0.84	(0.65, 1.08)
Total fractureb							0.95
<200	1456	2.11	1391	2.09	1.01	(0.93, 1.08)
200–<400	708	2.07	771	2.25	0.93	(0.84, 1.03)
400–<600	966	2.32	967	2.26	1.03	(0.94, 1.13)
≥600	814	2.38	816	2.46	0.98	(0.89, 1.08)
Invasive colorectal cancer							0.72
<200	91	0.12	95	0.13	0.95	(0.71, 1.27)
200–<400	46	0.12	60	0.16	0.79	(0.54, 1.17)
400–<600	70	0.15	60	0.13	1.21	(0.85, 1.71)
≥600	43	0.11	48	0.13	0.84	(0.56, 1.28)
Invasive breast cancer							0.03
<200	276	0.37	300	0.42	0.89	(0.76, 1.05)
200–<400	178	0.49	168	0.45	1.10	(0.89, 1.36)
400–<600	203	0.45	196	0.42	1.04	(0.85, 1.27)
≥600	181	0.49	139	0.38	1.28	(1.03, 1.60)
In situ breast cancer							0.31
<200	73	0.10	81	0.11	0.87	(0.64, 1.20)
200–<400	37	0.10	45	0.12	0.83	(0.54, 1.28)
400–<600	44	0.10	66	0.14	0.66	(0.45, 0.97)
≥600	39	0.11	40	0.11	0.91	(0.58, 1.42)
Total cancer							0.07
<200	888	1.23	942	1.36	0.91	(0.83, 0.99)
200–<400	503	1.42	542	1.52	0.94	(0.83, 1.06)
400–<600	588	1.34	611	1.36	0.98	(0.88, 1.10)
≥600	529	1.49	472	1.34	1.11	(0.98, 1.26)
Coronary heart disease							0.16
<200	339	0.45	338	0.47	0.96	(0.82, 1.11)
200–<400	142	0.38	166	0.44	0.86	(0.69, 1.08)
400–<600	213	0.46	184	0.39	1.19	(0.98, 1.46)
≥600	159	0.42	136	0.37	1.13	(0.90, 1.43)
Stroke							0.68
<200	242	0.32	227	0.31	1.03	(0.86, 1.24)
200–<400	128	0.34	127	0.34	1.08	(0.84, 1.38)
400–<600	174	0.38	153	0.32	1.18	(0.95, 1.47)
≥600	130	0.34	132	0.36	0.97	(0.76, 1.24)
Total death							0.19
<200	632	0.83	655	0.89	0.93	(0.83, 1.03)
200–<400	312	0.83	352	0.92	0.91	(0.78, 1.06)
400–<600	410	0.88	429	0.90	0.98	(0.85, 1.12)
≥600	376	0.99	341	0.92	1.07	(0.92, 1.24)
Global index							0.13
<200	1025	1.39	1073	1.51	0.92	(0.84, 1.00)
200–<400	533	1.47	597	1.63	0.90	(0.80, 1.01)
400–<600	691	1.54	709	1.55	1.01	(0.91, 1.13)
≥600	617	1.69	550	1.53	1.04	(0.93, 1.17)

^aFrom a proportional hazards model stratified by prevalent condition (where appropriate), age, hormone therapy and diet modification randomization arm, and trial phase (time-dependent). Time to event equals 0 on date of randomization.

^bAll nonhip fractures use adjudicated data during the clinical trial and self-reported data thereafter.